SpotitEarly

Website

SpotitEarly, Inc.

1 Investors
Biotechnology and Health Technology
ENGLEWOOD, NJ

SpotitEarly, Inc. is a biotechnology startup developing a non-invasive, at-home breath test for the early detection of multiple cancers. The company utilizes a unique bio-hybrid approach that combines the superior olfactory senses of trained canines with a proprietary artificial intelligence platform to analyze breath samples. This method aims to make early cancer screening more accessible, accurate, and less invasive than traditional procedures.

Products & Team

At-Home Early Cancer Detection Breath Test

Cancer Diagnostic TestSeed

This is a non-invasive screening tool for the early detection of breast, lung, colorectal, and prostate cancers. Consumers use an at-home kit to provide a breath sample, which is then mailed to SpotitEarly's lab for analysis. At the lab, trained canines sniff the sample, and their physiological and behavioral signals are monitored by the LUCID AI platform to determine the result.

Value Proposition

The test addresses the critical issue of low participation in early cancer screening by providing a more accessible, affordable, and less invasive alternative to traditional methods like mammograms and colonoscopies, potentially increasing early detection rates.

Pain Points

The product addresses customer aversion to invasive procedures, the high cost associated with some diagnostic tests, and the inconvenience of scheduling and attending appointments for traditional screenings.

Non-invasive breath sample collectionAt-home convenienceDetection of four common cancers (breast, lung, colorectal, prostate)Analysis using trained canines and a proprietary AI platform (LUCID)Reported 94% accuracy rate in clinical trials
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
ENGLEWOOD, NJ
Primary headquarters

Funding History

Total Raised:
$10.0K
E

Equity Offering

July 2025
$20.0M
Target
Progress
0%
Raised
$10.0K
Target
$20.0M
#000100487825000006